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Abstract 
Background: PM100117 and PM100118 are glycosylated polyketides with remarkable antitumor activity, which 
derive from the marine symbiotic actinobacteria Streptomyces caniferus GUA-06-05-006A. Structurally, PM100117 and 
PM100118 are composed of a macrocyclic lactone, three deoxysugar units and a naphthoquinone (NQ) chromophore 
that shows a clear structural similarity to menaquinone.
Results: Whole-genome sequencing of S. caniferus GUA-06-05-006A has enabled the identification of PM100117 
and PM100118 biosynthesis gene cluster, which has been characterized on the basis of bioinformatics and genetic 
engineering data. The product of four genes shows high identity to proteins involved in the biosynthesis of menaqui-
none via futalosine. Deletion of one of these genes led to a decay in PM100117 and PM100118 production, and to the 
accumulation of several derivatives lacking NQ. Likewise, five additional genes have been genetically characterized to 
be involved in the biosynthesis of this moiety. Moreover, the generation of a mutant in a gene coding for a putative 
cytochrome P450 has led to the production of PM100117 and PM100118 structural analogues showing an enhanced 
in vitro cytotoxic activity relative to the parental products.
Conclusions: Although a number of compounds structurally related to PM100117 and PM100118 has been discov-
ered, this is, to our knowledge, the first insight reported into their biosynthesis. The structural resemblance of the NQ 
moiety to menaquinone, and the presence in the cluster of four putative menaquinone biosynthetic genes, sug-
gests a connection between the biosynthesis pathways of both compounds. The availability of the PM100117 and 
PM100118 biosynthetic gene cluster will surely pave a way to the combinatorial engineering of more derivatives.
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Background
Actinobacteria is an extensive phyla within the domain 
bacteria with a wide distribution in nature, encompass-
ing both terrestrial and aquatic environments [1, 2]. 
Numerous actinobacteria species have an outstanding 
medical value as producers of cancer chemotherapeutic 
drugs [3], among other biologically active compounds [4, 
5]. Terrestrial actinobacteria are the source of the vast 
majority of natural antitumor agents discovered up to 
date, many of which are the base of currently available 
chemotherapeutic treatments or are in advance clinical 
trials [6]. However, in spite of the enormous potential of 
soil actinobacteria as producers of antitumor agents, the 
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rate of discovery of new antitumor drugs and other bio-
active compounds from the terrestrial environment has 
nowadays decayed [7–9]. This, together with the world-
wide-rising occurrence of cancer and the appearance of 
multi-drug resistant tumor cell lines, urges to extend the 
screening of new and improved chemotherapeutic prod-
ucts to less explored environments.
Ocean is a major component of the biosphere and an 
example of unexploited habitat with the potential to host 
the chemical and biological diversity required for the dis-
covery of novel anticancer agents. A staggering diversity 
of actinobacteria species has been isolated from different 
marine substrates such as sediments seawater, seaweeds 
or mangroves [2]. Furthermore, tissues of mollusks and 
invertebrates are the niche of remarkably diverse symbi-
otic actinobacteria populations many of which could have 
lost the ability to grow independently of their host [10]. 
Some of the symbiotic functions attributable to sym-
biotic actinobacteria entail the production of bioactive 
secondary metabolites (e.g., for host defense) with poten-
tial pharmaceutical significance. Indeed, many natural 
products isolated from diverse marine invertebrates have 
been proven to be produced by their symbiotic micro-
organisms. That is the case, for example, of the dibenzo-
diazepinone diazepinomicin [11], the thiodepsipeptide 
thiocoraline [12] and the polyketide bryostatin [13], three 
potent antitumor drug leads; or the tetrahydroisoquino-
line ecteinascidin 743 [14], an anticancer drug in current 
clinical use.
Although the screening of antitumor natural products 
from yet unexploited environments is a valid plan to 
alleviate the problem of the apparent chemical exhaus-
tion of terrestrial sources, the use of metabolic engineer-
ing and combinatorial biosynthesis strategies intended 
to generate novel analogues from known natural agents 
[15–17], can be a no less interesting approach. How-
ever, application of these genetic engineering strategies 
requires to a certain extent detailed knowledge on the 
genetic and biochemical basis of the biosynthesis of rel-
evant natural metabolites. Hence, the identification and 
characterization of biosynthetic gene clusters is not only 
an invaluable tool for the elucidation of the biosynthesis 
pathway of bioactive natural agents, but also an essential 
requirement for tackling the combinatorial engineer-
ing of novel analogues. In parallel with the development 
of these genetic engineering approaches, advances in 
next-generation whole-genome sequencing techniques 
[18] has favored the availability of a growing number of 
genomes from actinobacteria producing clinical attrac-
tive bioactive compounds. Mining of these genomes 
has enabled the identification and analysis of an expo-
nentially increasing number of clusters [19], setting the 
stage for subsequent combinatorial engineering of novel 
derivatives. Furthermore, genome analysis by enhanced 
bioinformatics platforms associated to database [20–24] 
allows for disclosing the chemical diversity potentially 
hosted in theses actinobacteria, contributing to widen 
the availability of natural products by activation of cryp-
tic clusters [19].
In a recent publication [25], the discovery of PM100117 
and PM100118 was reported. These glycosylated polyke-
tide compounds, with remarkable antitumor activity, are 
produced by Streptomyces caniferus GUA-06-05-006A, 
a symbiotic actinobacteria isolated from the marine 
sponge Filograna sp. The structures of PM100117 and 
PM100118, consisting of a macrocyclic lactone, three 
deoxysugars and a 1, 4-naphthoquinone chromophore 
(Fig.  1), share a clear similarity with other antitumor 
polyketide compounds, including langkolide [26] and 
the promising anticancer drug lead GT35 [27]. Given 
their attractive as potential anticancer clinical drugs, 
PM100117 and PM100118 represent interesting targets 
for the combinatorial engineering of novel derivatives. 
The goals of this work were the identification and charac-
terization of the PM100117 and PM100118 biosynthesis 
gene cluster, and engineering the gene cluster to generate 
novel derivatives with improved biological activity.
Results
Sequencing and bioinformatics analysis of S. caniferus 
GUA‑06‑05‑006A genome
The first step to accomplish the identification of the 
PM100117 and PM100118 biosynthesis gene cluster was 
sequencing the S. caniferus GUA-06-05-006A chromo-
some. Whole-genome sequencing of this strain gener-
ated a total number of 548,579 paired-end reads with an 
average length of 372.5 nucleotides, producing a total 
sequence of 204.3  Mb. This represents a 20-fold cover-
age of the chromosome sequence, which is estimated in 
9.8  Mb. De novo assembly of those sequences resulted 
in 907 contigs. Median (N50) of the contig assembly was 
20.9 Kb, and the largest was around 119.3 Kb. Subsequent 
contig arrangement rinsed 33 scaffolds (mean: 276.2 Kb; 
N50: 1.5 Mb) generating a draft genome of 9.1 Mb with 
a G  +  C content of 70.63  %. In silico genome analyses 
with the antibiotics and Secondary Metabolite Analy-
sis Shell (antiSMASH) algorithm [22] revealed the pres-
ence of 8582 open reading frames (ORFs), having at least 
5045 proteins an assigned putative function. Sequence 
analyses with antiSMASH also showed the presence of 
32 gene clusters potentially involved in the biosynthesis 
of secondary metabolites. Seven of these clusters were 
identified as containing gene sequences belonging to the 
type I (four clusters), II (two clusters) and III (one cluster) 
family of polyketide synthases (PKS). Likewise, genome 
sequence analysis detected nine additional gene clusters 
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comprising modular enzyme-coding genes such as non-
ribosomal peptide synthetase (NRPS, seven clusters) and 
hybrid PKSI-NRPS genes (two clusters). Other products 
from these gene clusters include one nucleoside, five ter-
penes and three butyrolactones, as well as compounds 
with a peptidic backbone such as three siderophores, 
three lantipeptides and one ectoine.
Identification of PM100117 and PM100118 biosynthetic 
gene cluster
PM100117/18 chemical structures have been previously 
elucidated by nuclear magnetic resonance (NMR) spec-
troscopy [25]. They contain a 48 carbons aglycone that 
is likely biosynthesized by the condensation of 21 ketide 
moieties. The aglycone forms a 36-membered macro-
lactone ring and is decorated with a side chain consist-
ing of three 2,6-dideoxy sugars and a 1,4-naphtoquinone 
chromophore (Fig.  1). The first sugar moiety attached 
to the aglycone is l-axenose, which can be linked 
either to l-2-deoxy-fucose (PM100117) or l-rhodinose 
(PM100118) as second sugar. The second sugar unit is 
linked to the naphtoquinone moiety, which shares a clear 
structural similarity with menaquinone (MK). An l-rho-
dinose moiety attached to the naphtoquinone structure 
represents the third deoxysugar of the PM100117/18 
glycosylation pattern. Based on these structural features, 
glycosyltransferase and sugar biosynthetic genes, as 
well as a minimum of 21 PKS modules, are presumably 
involved in the biosynthesis of PM100117/18. Among 
the seven PKS gene clusters identified by antiSMASH, 
one of them contained ORFs designated with such puta-
tive functions, representing the most suitable candidate 
cluster to accomplish PM100117/18 biosynthesis. The 
putative PM100117/18 cluster covers a 171  kb region 
and contains 54 ORFs (Fig. 2a) coding for proteins with 
the putative functions listed in Table 1. The involvement 
of this cluster in PM100117/18 biosynthesis was dem-
onstrated by inactivation of the PKS gene gonP1. The 
analysis of the resulting mutant strain showed that gonP1 
inactivation abolished PM100117/18 biosynthesis, thus 
confirming the implication of this cluster in the produc-
tion of PM100117/18 (Fig. 2b).
In silico analysis of PM100117 and PM100118 gene cluster 
and proposed biosynthesis pathway
Polyketide ring and post‑PKS modifications
The PM100117/18 cluster encompasses seven contigu-
ous PKS genes (gonP1–gonP7) coding for a multimodu-
lar PKS that comprises a loading domain (LD) and 20 
extension modules (M1–M20), in agreement with the 
21 condensation steps required for the biosynthesis 
of the PM100117/18 macrolide ring. Sequence analy-
sis of GonP1–GonP7 allowed to define ketosynthase 
(KS or KSQ), acyltranferase (AT), ketoreductase (KR), 
dehydratase (DH), enoylreductase (ER) and acyl-car-
rier-protein (ACP) domains. LD contains a ketosyn-
thase (KSQ) domain, in which the essential cysteine of 
the conserved DTxCSxS sequence at the active site is 
replaced by glutamine [28]. Sequence alignment of the 
cluster PKS domains active sites is shown as supplemen-
tary data (Additional file 1: Figure S1). AntiSmash analy-
sis also predicted substrate specificity of AT domains 
within the modular PKS for methylmalonyl-CoA (ATp) 
in seven modules (LD, M1–M4, M14 and M19) and for 
malonyl-CoA (ATa) in 14 modules (M5–M13, M15–
M18 and M20). The organization of the PKS genes and 
the proposed biosynthesis pathway of the PM100117/18 
macrolide backbone are shown in Fig.  3. Overall, the 
predicted substrate specificity of AT domains alongside 
the disposal of the defined KR, DH and ER domains are 
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Fig. 1 Chemical structures of PM100117 and PM100118. Deoxysugar moieties are indicated: (a) l-axenose, (b) l-rhodinose (R=H) or l-2-deoxi-
fucose (R=OH), (c) l-rhodinose
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consistent with the hypothetical elongation through col-
linear reactions of the polyketide chain. Only a few dis-
crepancies are found between this biosynthesis model 
and the chemical structure of the polyketide moiety, sug-
gesting the inactivity/inability of certain PM100117/18 
PKS domains or the occurrence of post-PKS modifica-
tions. The presence of a DH domain in M6 (GonP3), as 
well as a DH and an ER domain in M9 (GonP4), appar-
ently disturbs the collinear biosynthesis of the polyketide, 
given the presence of hydroxyl groups at carbon (C) 31 
and C25 of the polyketide skeleton (Fig.  3). Nonethe-
less, a detailed sequence analysis of the M6 DH domain 
revealed an arginine in place of an otherwise conserved 
histidine in the NADPH motif LxxHxxxGxxxxP [29] at 
the active site (Aditional file 1: Figure S1). This, together 
with a shorter C-terminal sequence in comparison with 
other DH domains within the cluster PKSs, suggests that 
M6 DH is most possibly inactive. By contrast, sequence 
analysis did not show any alteration of the M9 DH and 
ER domains, which are probably functional. Thus, 
the unexpected presence of these domains could be 
explained by a “domain skipping” mechanism prevent-
ing dehydrogenation of C25 during polyketide elongation 
[30]. Alternatively, the presence of a hydroxyl group at 
C25 can be the result of a post-PKS modification follow-
ing polyketide biosynthesis, catalyzed by any of the two 
putative oxygenases coded by gonCP and orf9. Moreover, 
the involvement of the M13 DH domain (GonP5) in the 
polyketide biosynthesis is unlikely due to the lack of a KR 
domain in this module catalyzing a previous ketoreduc-
tion reaction. One last inconsistency is found between 
the substrate specificity of the AT domain of M19 
(GonP7), which is predicted to utilize methylmalonyl-
CoA as extension unit, and the absence of a methyl group 
at C4 (Fig.  3). However, the presence in this domain of 
a YASH motif, which specifies utilization of methylmal-
onyl-CoA [31], can be confirmed as shown in the align-
ment of cluster AT active sites (Additional file 1: Figure 
S1). Despite this, no PM100117/18 analogues containing 
an additional methyl group at C4 have been detected in S. 
caniferus GUA-06-05-006A cultures.
Sugars biosynthesis
A distinctive feature of the PM100117/18 biosynthe-
sis gene cluster, among the 32 clusters for secondary 
metabolites hosted by S. caniferus GUA-06-05-006A, is 
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Fig. 2 Identification and organization of the PM100117 and PM100118 biosynthetic gene cluster. a Organization of the PM100117 and PM100118 
gene cluster. The proposed gene functions are listed in Table 1. b UPLC analysis of PM100117 (1) and PM100118 (2) production in Streptomyces 
caniferus GUA-06-05-006A wild type (GUA) and mutant gonP1−
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Table 1 Deduced functions of ORFs in PM100117 and PM100118 biosynthetic gene cluster
Gene Deduced aa.  
length
Protein homologue  
(accession no.)
Identity/ 
similarity (%)
Proposed function
orf1 264 WP_030324639.1 84/92 Aspartate dehydrogenase
orf2 265 WP_030324637.1 77/83 Hydrolase
orf3 173 WP_018535062.1 94/98 Cupin domain-containing protein
orf4 228 EDY62802.1 81/86 3-Ketoacyl-(acyl-carrier-protein) reductase
orf5 260 WP_005320771.1 83/89 Short-chain dehydrogenase
orf6 541 WP_033304767.1 82/87 Acetolactate synthase
orf7 313 WP_005320767.1 79/85 Ferredoxin
orf8 75 WP_031101148.1 70/75 Hypothetical protein
orf9 337 WP_033304770.1 88/93 3-Phenylpropionate dioxygenase
gonMR 176 WP_030624728.1 92/95 MarR family transcriptional regulator
gonL1 959 WP_006607813.1 86/90 LuxR family transcriptional regulator
gonL2 241 EJJ02892.1 80/84 LuxR family transcriptional regulator
gonL3 939 WP_006607811.1 80/87 LuxR family transcriptional regulator
gonD1 469 WP_006607808.1 90/94 NDP-hexose 2,3-dehydratase
gonP1 4219 AJE81080.1 60/69 Type I polyketide synthase
(loading module and modules 1 and 2)
gonP2 4939 AAZ94388.1 57/68 Type I polyketide synthase
(modules 3 to 5)
gonP3 3959 EJJ02484.1 86/89 Type I polyketide synthase
(modules 6 and 7)
gonP4 5234 EJJ02491.1 86/90 Type I polyketide synthase
(modules 8 to 10)
gonP5 8461 EDX25447.1 55/67 Type I polyketide synthase
(modules 11 to 15)
gonP6 5238 EJJ02498.1 87/90 Type I polyketide synthase
(modules 16 to 18)
gonP7 3641 EJJ02497.1 87/91 Type I polyketide synthase
(modules 19 and 20)
gonF1 67 WP_006608219.1 76/80 Ferredoxin
gonG1 415 ABO28820.1 66/80 Glycosyltransferase
gonGS 358 WP_006608216.1 94/97 Glucose-1-phosphate thymidylyltransferase (glucose 
synthase)
gonD2 333 WP_040902050.1 91/93 dTDP-glucose 4,6-dehydratase
gonR1 356 WP_051007140.1 70/79 NDP-4-keto-6-deoxyhexose reductase
gonG2 408 WP_006608213.1 74/83 Glycosyltransferase
gonD3 433 BAP34744.1 73/84 NDP-hexose-3,4-dehydratase
gonSL 1107 WP_006608212.1 68/78 AMP-dependent synthetase and ligase (acyl-CoA 
ligase, DH, KR, ACP)
gonS1 347 WP_040902110 82/91 3-oxoacyl-ACP synthase III
gonA 146 WP_040902049 72/84 Cold-Shock DNA-binding domain-containing protein
gonG3 402 WP_006608209 55/68 Glycosyltransferase
gonMT 345 WP_014208548 49/62 Methylase involved in ubiquinone/menaquinone 
biosynthesis
gonS2 344 WP_040246457 81/90 3-Oxoacyl-ACP synthase III
gonP8 2408 WP_006608212 58/59 Type I polyketide synthase
(loading module and extension module 1)
gonG4 368 WP_042158955 89/93 Glycosyltransferase
gonT1 286 WP_040902100.1 83/92 Multidrug ABC transporter permease
gonT2 260 WP_006608193.1 89/94 Multidrug ABC transporter permease
gonR2 319 AAB63047.1 49/63 dTDP-4-keto-2,3,6-trideoxyhexulose reductase
gonE 211 WP_006608191.1 83/89 dTDP-4-deoxyglucose 3,5-epimerase
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the presence of ORFs with assigned putative functions 
implicated in biosynthesis or transfer of deoxysugars. 
Based on these putative functions the biosynthesis path-
way of l-axenose, l-2-deoxi-fucose and l-rhodinose can 
be predicted (Fig. 4). Proteins GonGS and GonD2, puta-
tive NDP-glucose synthase and NDP-glucose 4,6-dehy-
dratase, respectively, might catalyze the biosynthesis of 
the key intermediate NDP-4-keto-6-deoxy-d-glucose 
[32], which should be then transformed into NDP-4-
keto-2,6-dideoxy-d-glucose (2,6-DG) by the activity of 
the putative NDP-hexose 2,3-dehydratase GonD1 and 
the putative NDP-hexose 3-ketoreductase GonR3. Bio-
synthesis of l-2-deoxi-fucose from 2,6-DG requires 
3,5-epimerization (3,5-EPI) and C4-ketoreduction (C4-
KR) reaction steps, which are possibly catalyzed by 
the putative dTDP-deoxyglucose 3,5-epimerase GonE 
and one of the putative NDP-4-keto-6-deoxyhexose 
reductases GonR1 or GonR2, respectively. In addi-
tion to 3,5-EPI and C4-KR reactions, biosynthesis of 
l-axenose from 2,6-DG involves a C3-metylation step, 
presumably catalyzed by the putative NDP-hexose-3-C-
methyltransferase GonCM. Moreover, biosynthesis 
of l-rhodinose requires the C3-dehydration reaction 
of 2,6-DG, possibly catalyzed by the putative NDP-
hexose-3,4-dehydratase enzyme GonD3, followed by 
3,5-EPI and C4-KR. After macrolactone formation, 
four putative glycosyltransferase-coding genes (gonG1, 
gonG2, gonG3 and gonG4) could be involved in the 
transfer of the three deoxysugar moieties to generate 
PM100117/18.
Naphthoquinone (NQ) biosynthesis
A further peculiarity of the PM100117/18 biosynthe-
sis cluster is the presence of four ORFs (gonM1, gonM2, 
gonM3 and gonM4) with high identity to genes previ-
ously reported as involved in menaquinone biosynthesis 
via futalosine. This newly discovered MK pathway was 
first described in S. coelicolor A3(2) [33–35] but bio-
informatics analyses suggest its presence also in other 
bacteria lacking the classic MK biosynthetic pathway via 
isochorismate [33, 36, 37]. Sequence analysis reveals a 
high degree of identity (I) and similarity (S) of GonM1, 
GonM2 and GonM4 to the S. coelicolor A3(2) proteins 
SCO4506/MqnA (I: 60.1 %, S: 74.4 %), SCO4550/MqnC 
(I: 85  %, S: 91.6  %) and SCO4326/MqnD (I: 69.5  %, S: 
77.1  %), respectively. These S. coelicolor A3(2) proteins, 
together with SCO4327/MqnB, have been previously 
shown to be involved in the biosynthesis of the futalo-
sine MK pathway intermediate 1,4-dihydroxy 6-napthoic 
acid (DH6N) [33–35]. Furthermore, GonM3 shares 
sequence resemblance with SCO4494/MqnE (I: 93 %, S: 
96.4), a protein proposed to catalyze the biosynthesis of 
aminodeoxyfutalosine [38], an alternative substrate for 
MK biosynthesis. An additional copy of genes coding for 
proteins with high identity and similarity to S. coelicolor 
A3(2) MqnA (I: 56.6  %, S: 62.2  %), MqnB (I: 68.1  %, S: 
72.9 %), MqnC (I: 92.7 %, S: 97.0 %) and MqnD (I: 72.2 %, 
S: 75.7  %) has been detected in the S. caniferus GUA-
06-05-006A genome, outside the PM100117/18 gene 
cluster. The structural similarity of DH6N with the NQ 
unit led us to suspect a role of genes gonM1–gonM4 on 
Table 1 continued
Gene Deduced aa.  
length
Protein homologue  
(accession no.)
Identity/ 
similarity (%)
Proposed function
gonCM 410 AKT74284.1 79/87 NDP-hexose-3-C-methyltransferase
gonH1 252 WP_006608189.1 79/88 Hypothetical protein
gonT 256 WP_006608180.1 90/94 Thioesterase
gonM1 301 WP_046708157.1 77/86 Menaquinone biosynthesis protein (chorismate 
dehydratase)
gonM2 407 EJJ02566.1 96/97 Menaquinone biosynthesis protein (dehypoxanthine 
futalosine cyclase)
gonF2 101 WP_006608177.1 94/96 Ferredoxin
gonM3 387 WP_006608176.1 98/99 Menaquinone biosynthesis protein (aminofutalosine 
synthase)
gonM4 291 WP_006608174.1 87/91 Menaquinone biosynthesis protein (1,4-dihydroxy-
6-naphthoate synthase)
gonR3 364 WP_006608173.1 91/94 NDP-hexose 3-ketoreductase
gonCP 482 WP_006608172.1 91/95 Cytochrome P450
orf10 264 WP_030985702.1 88/92 3-Oxoacyl-ACP reductase
orf11 128 WP_053688399.1 86/91 HxlR family transcriptional regulator
orf12 174 WP_051733431.1 93/96 Hypothetical membrane protein
orf13 355 WP_037651728.1 90/93 NADPH: quinone reductase
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the biosynthesis of this compound. Other ORFs poten-
tially involved in the biosynthesis of NQ code for AMP-
dependent synthetase and ligase GonSL, 3-oxoacyl-ACP 
synthase III GonS1 and GonS2, type I PKS GonP8 and 
methyltransferase GonMT. GonSL contains an appar-
ently active CoA ligase (CAL) and ACP domain, and a 
KR and DH domain with important amino acid substitu-
tions (Additional file 1: Figure S1). The putative PKS gene 
gonP8 consists of a loading module containing a CAL 
and an ACP domain, and an extension module with a KS, 
ATp, KR, DH and ACP domain, all of them with no sig-
nificant active site amino acid replacements (Additional 
file 1: Figure S1).
The proposed biosynthesis pathway of the 
PM100117/18 NQ moiety is depicted in Fig.  5. GonM1 
(MqnA), GonM2 (MqnC), GonM4 (MqnD) and a futalo-
sine hydrolase (MqnB) enzyme coded by a gene external 
to the PM100117/18 cluster could catalyze the biosyn-
thesis of DH6N, which would be then methylated by the 
putative methyltransferase GonMT to form 3-methyl-
DH6N (Fig. 5). Interestingly, GonMT is only 11 % iden-
tical to SCO4556, which is the enzyme proposed to 
catalyze the quinone-ring C2-methylation in the last 
step of MK biosynthesis [33–35]. There is no available 
information to deduce the possible mechanism by which 
3-methyl-DH6N is elongated with a propionate unit to 
form the NQ moiety. However, based on the fatty acid 
activation process catalyzed by fatty acyl-AMP ligases 
[39], we could speculate that the putative synthetase-
ligase GonSL could catalyze the synthesis of a 3-methyl-
DH6N-AMP adduct, and the subsequent transfer of 
3-methyl-DH6N to the pantetheine group of its own 
ACP domain. In a next step, 3-methyl-DH6N might be 
transferred to the LD of PKS GonP8, and then elongated 
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Fig. 3 Proposed biosynthesis pathway of PM100117 and PM100118 polyketide skeleton. LD loading domain, M1–M20 extension modules. Polyke-
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by the GonP8 extension module. Binding of 3-methyl-
DH6N-AMP to the GonSL ACP domain, and its fol-
lowing transfer to the LD of PKS GonP8, may require 
the participation of any of the putative 3-oxoacyl-ACP 
synthase III (KSIII) enzymes coded by genes gonS1 and 
gonS2. The involvement of KSIII proteins in the priming 
of starter units alternative to malonyl-CoA and methyl-
malonyl-CoA has been previously reported in the bio-
synthesis of a number of compounds [40–42]. Likewise, 
the mechanism by which NQ is eventually transferred 
to PM100117/18 may also require intervention of KSIII, 
GonP8 or both.
Pathway regulation
Four ORFs (gonMR, gonL1, gonL2 and gonL3) could be 
responsible for PM100117/18 pathway regulation as 
they code for proteins with high sequence resemblance 
to transcription regulatory proteins. GonMR contains 
a helix-turn-helix (HTH) motif (smart00347) highly 
conserved among members of the MarR family of pro-
tein regulators. GonL1 and GonL3 contain a N-termi-
nal nucleoside triphosphate binding motif (pfam13191) 
and a HTH domain of the LuxR-type at de C terminus 
(smart00421), which are distinctive functional features 
of the LAL family of transcription factors [43, 44]. In 
addition to a LuxR-like C-terminal HTH motif, GonL2 
contains a PAS-sensor binding fold at the N terminus 
(cd00130). This domain is designated PAS because of 
its homology to the Drosophila period protein (Per), the 
aryl hydrocarbon receptor nuclear translocator protein 
(ARNT) and the Drosophila single-minded protein (Sim) 
[45].
PM100117 and PM100118 transport
ORFs gonT1 and gonT2 code for a putative ATP-binding 
cassette (ABC) transport system. ABC transport com-
plexes are comprised of a hydrophilic protein containing 
an ATP-binding domain and a hydrophobic protein with 
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Fig. 4 Schematic representation of the proposed biosynthesis pathway of PM100117 and PM100118 deoxysugar moieties
Page 9 of 19Salcedo et al. Microb Cell Fact  (2016) 15:44 
six membrane-spanning domains [46]. GonT1 shares 
high sequence identity and similarity with ABC-type 
membrane permeases and its analysis with the TMHMM 
server predicts the formation in this protein of six hydro-
phobic transmembrane domains. Conversely, GonT2 
displays an ABC-like nucleoside triphosphate hydrolase 
domain (cl21455), which in combination with the puta-
tive permease GonT1 could produce a complex to facili-
tate PM100117/18 transport across the membrane.
Cluster boundaries analysis
On the cluster left side, genes gonMR, gonL1, gonL2 and 
gonL3 were presumed to code for pathway-specific regu-
lators for PM100117/18 biosynthesis, and orf9, which 
codes for a putative dioxygenase, was a candidate gene 
to accomplish polyketide post-PKS oxygenations. Thus, 
to verify this boundary, we performed ultra-performance 
liquid chromatography (UPLC) analysis of PM100117/18 
production in mutant strains ΔgonL1, ΔgonMR and 
Δ5201 in which gonL1, gonMR and orf9, respectively, 
have been deleted. The result of this analysis showed 
that in Δ5201 PM100117/18 production was not altered 
with respect to S. caniferus GUA-06-05-006A wild type. 
By contrast, in ΔgonL1 and ΔgonMR, PM100117/18 
biosynthesis was absent or severely decreased (Fig.  6a). 
Curiously, deletion of these genes induced the produc-
tion of a new compound (NR), with a maximum absorp-
tion wavelength at 260  nm, apparently not related to 
PM100117/18 biosynthesis. Since PM100117/18 deriva-
tives lacking small functional groups could possess reten-
tion times close to those of the parental products, Δ5201 
extracts were also analyzed by LC-MS, confirming that 
peaks labeled as 1 and 2 indeed correspond to PM100117 
and PM100118, respectively. These results verified the 
involvement of genes gonL1 and gonMR in PM100117/18 
biosynthesis, presumably coding for positive pathway-
specific transcriptional regulators. PM100117/18 pro-
duction was partially recovered in mutant strains ΔgonL1 
and ΔgonMR when a copy of gonL1 and gonMR, respec-
tively, was re-introduced (Additional file  1: Figure S2). 
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The cluster left border is thus apparently defined by 
gonMR. Upstream to this gene, antiSMASH detected 
nine ORFs coding for proteins with putative functions 
(Table  1) likely not pertaining to PM100117/18 biosyn-
thesis. Most of these putative activities are related to 
oxidation-reduction reactions, such as ferredoxin (orf7), 
short-chain dehydrogenase (orf5), 3-ketoacyl-ACP reduc-
tase (orf4) and aspartate dehydrogenase (orf1), as well as 
a cupin domain-containing protein (orf3).
On the cluster right side, gene gonCP has been dem-
onstrated by genetic engineering to be involved in the 
polyketide post-PKS oxygenation. Detailed data on 
this finding are described in section below. Adjacent to 
gonCP, antiSMASH detected ORFs coding for proteins 
with putative activities 3-oxoacyl-ACP reductase (orf10), 
HxlR family transcriptional regulator (orf11), hypotheti-
cal membrane protein (orf12) and NADPH-dependent 
quinone reductase (orf13). Hence, in order to verify the 
cluster right boundary, strains Δ5257, Δ5259 and Δ5261, 
which lack orf10, orf11 and orf13, respectively, were 
assessed for PM100117/18 production by UPLC. As 
shown in Fig.  6b, deletion of these genes does not have 
any effect on PM100117/18 biosynthesis, confirming that 
they do not belong to the cluster. Therefore, the right 
cluster boundary seems to be defined by gene gonCP.
Generation and characterization of novel PM100117/18 
derivatives
The main goal of this work was engineering novel 
PM100117/18 analogues with improved antitumor 
properties. We first sought to obtain structural ana-
logues lacking the NQ moiety. For that purpose, a series 
of mutant strains affected in NQ biosynthesis putative 
genes (Fig.  5) was generated by disruption of gonP8, or 
individual deletion of gonM4, gonMT, gonSL, gonS1 or 
gonS2. The resulting strains, gonP8−, ΔgonM4, ΔgonMT, 
ΔgonSL, ΔgonS1 and ΔgonS2, were examined for 
PM100117/18 production by UPLC at 254 nm (Fig. 7a). 
These analyses did not detect PM100117/18 biosynthesis 
in gonP8−, ΔgonMT, ΔgonSL, ΔgonS1 and ΔgonS2. Only 
in ΔgonM4 some traces of PM100117/18 were detected 
(Fig. 7a). To assess whether the reason of these changes 
in the PM100117/18 production level was the absence or 
decrease of NQ biosynthesis, we examined the accumula-
tion of PM100117/18 intermediates lacking the NQ moi-
ety in the mutant strains. It is important to note that loss 
of the NQ unit causes a change in the maximum absorp-
tion wavelength with respect to the parental compounds, 
shifting from 254 to 216 nm. UPLC and LC-MS analysis 
at 216 nm detected in the six mutant strains several com-
pounds (Fig. 7b, triangles) with the expected absorption 
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Fig. 6 Cluster boundaries delimitation. UPLC analysis of PM100117 (1) and PM100118 (2) production in Streptomyces caniferus GUA-06-05-006A 
wild-type (GUA) and mutant strains a Δ5201, ΔgonMR and ΔgonL1 (left border) and b Δ5257, Δ5259 and Δ5261 (right border). NR compound not 
related to PM100117/18
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spectra. In addition, two of these products (3 and 4) pos-
sessed molecular weights compatible with PM100117 
[1, UPLC Rt =  5.182  min, m/z 1601.9 (M +  Na)+] and 
PM1001118 [2, UPLC Rt  =  5.536  min, m/z 1585.9 
(M  +  Na)+] biosynthetic intermediates lacking the NQ 
moiety. The chemical structures of compounds 3 [UPLC 
Rt  =  4.14  min, m/z 1231.7 (M  +  Na)+] and 4 [UPLC 
Rt = 4.21 min, m/z 1215.7 (M + Na)+] were determined 
by NMR (Additional file  2: Figure S5), confirming that 
both products correspond to PM100118 analogues lack-
ing the NQ moiety (Fig.  7c). Interestingly, compound 3 
carries an additional hydroxyl group at the aglycone C18, 
which is not present in any of the parental products, sug-
gesting that this derivative could belong to a PM100118 
shunt biosynthetic pathway. Mutant complementa-
tion with the corresponding genes partially restored 
PM100117/18 production (Additional file  1: Figure S2). 
These results confirm the involvement of genes gonM4, 
gonMT, gonSL, gonS1, gonS2 and gonP8 in the biosynthe-
sis and/or transfer of the NQ unit to PM100117/18.
The in  vitro antitumor activity of 3 and 4 was deter-
mined by measuring their GI50 (50  % inhibition on cell 
growth), TGI (total growth inhibition) and LC50 (50  % 
cell death) concentrations [47], against cancer cell lines 
A549 (human lung carcinoma cells), PSN1 (pancreas car-
cinoma), MDA-MB-231 (human breast adenocarcinoma) 
and HT29 (human colorectal carcinoma). The values of 
these three antitumor indicators for compounds 3 and 
4 were remarkably higher than those of PM100117/18, 
indicating a weaker cytotoxic activity of the deriva-
tive compounds in comparison with the natural drugs 
(Table 2).
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Fig. 7 Characterization of genes involved in the biosynthesis of the PM100117 and PM100118 naphthoquinone unit. Analysis of PM100117 (1) and 
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Given the cytotoxicity decay caused by the loss of the 
NQ moiety, we sought to perform a genetic manipula-
tion leading to minor modifications of the PM100117/18 
structure while preserving the NQ unit. With this aim, 
we deleted gonCP, which codes for a putative cytochrome 
P450 monooxygenase potentially involved in the oxy-
genation of the aglycone C16 and C17 (Fig.  3). UPLC 
analysis revealed the ability of the resulting mutant 
strain, ΔgonCP, to produce several compounds (triangles, 
Fig. 8a) with absorption spectra related to PM100117/18. 
Furthermore, analysis of fermentation extracts from 
ΔgonCP by LC-MS showed that two of these compounds, 
5 [UPLC Rt =  5.14  min, m/z 1587.9 (M +  Na)+] and 6 
[UPLC Rt =  5.50  min, m/z 1571.9 (M +  Na)+], possess 
molecular weights corresponding to PM100117 (1) and 
PM100118 (2) analogues, respectively, lacking a keto 
group. Compounds 5 and 6 were then purified and ana-
lyzed by NMR to determine their chemical structures 
(Additional file 2: Figure S5), confirming that they derive 
from PM100117 and PM100118, respectively, by loss of 
the C16 aglycone keto functional group (Fig.  8b). This 
confirms the implication of gene gonCP in C16 oxygena-
tion, but the question on the enzyme that catalyzes C17 
hydroxylation still remains. The production of the natural 
compounds was restored when gonCP was re-introduced 
in the ΔgonCP mutant (Additional file 1: Figure S2).
Likewise compounds 3 and 4, the antitumor activity of 
derivatives 5 and 6 was examined against various cancer 
cell lines. Interestingly, compound 5 possesses an in vitro 
cytotoxicity threefold to fourfold higher than its corre-
sponding parental product (1, PM100117) against A549 
and MDA-MB-231 cell lines, as indicated by the lower 
GI50, TGI and LC50 concentration values (Table  2). The 
GI50 concentration of this compound also showed an out-
standing 23-fold increase of antitumor activity, relative 
to PM100117, against HT29 tumor cells. However, this 
result is not concomitant with a similar decrease of the 
TGI and LC50 concentrations, which keep values close to 
that of compound PM100117. Additional analysis of 5 by 
antibiotic activity assays against Micrococcus luteus and 
Saccharomyces cerevisiae further confirms an enhanced 
bioactivity of this derivative with respect to the parental 
products (Additional file  1: Figure S3). PM100118 ana-
logue 6 showed a twofold to threefold improvement in 
the in vitro cytotoxic activity against the A549 cell line, as 
revealed by its lower GI50, TGI and LC50 values relative to 
the natural compound (2, PM100118).
Discussion
In this work, we have identified the PM100117 and 
PM100118 biosynthetic gene cluster, which has been 
characterized on the basis of bioinformatics analysis and 
genetic engineering data. The cluster spans a region of 
169 kb and contains 41 genes coding for all the putative 
functions presumably required for PM100117/18 biosyn-
thesis (Fig. 2; Table 1). From these activities, biosynthe-
sis of PM100117/18 can be predicted as follows. Firstly, 
a type I multimodular PKS containing a loading module 
and 20 extension modules, catalyzes the 21 condensation 
reactions required for the biosynthesis of the aglycone 
polyketide chain (Fig. 3). The macrolatone moiety is then 
decorated with two 2,6-dideoxysugar moieties. Next, the 
NQ unit is transferred to the second deoxysugar and then 
glycosylated with the third 2,6-dideoxysugar. The pres-
ence in the cluster of four putative glycosyltransferase 
genes is consistent with the PM100117/18 glycosylation 
pattern. One of the four glycosyltransferases might trans-
fer l-axenose to the first position of the glycosylation 
Table 2 In vitro antitumor activity of compounds 1–6
GI50 compound concentration that produces 50 % inhibition on cell growth as 
compared to control cells, TGI compound concentration that produces total 
growth inhibition as compared to control cells, LC50 compound concentration 
that produces 50 % cell death as compared to control cells, Nd values not 
determined
Compounds A549 (µM) HT29 (µM) MDA‑MB‑231  
(µM)
PSN1 (µM)
1
PM100117
 GI50 1.52 3.04 2.66 nd
 TGI 1.84 3.23 2.79 nd
 LC50 2.22 3.61 2.97 nd
2
PM100118
 GI50 2.24 1.92 1.73 nd
 TGI 3.13 2.81 2.75 nd
 LC50 4.28 4.09 4.16 nd
3
from mutant gonP8−
 GI50 >8.40 >8.40 >8.40 >8.40
 TGI >8.40 >8.40 >8.40 >8.40
 LC50 >8.40 >8.40 >8.40 >8.40
4
from mutant gonP8−
 GI50 >8.40 >8.40 >8.40 >8.40
 TGI >8.40 >8.40 >8.40 >8.40
 LC50 >8.40 >8.40 >8.40 >8.40
5
from mutant ∆gonCP
 GI50 0.38 0.13 0.71 0.90
 TGI 0.54 1.80 0.83 0.96
 LC50 0.77 2.50 1.03 1.03
6
from mutant ∆gonCP
 GI50 1.11 3.39 2.60 2.80
 TGI 1.17 4.30 2.80 3.00
 LC50 1.24 5.48 3.00 3.19
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profile. Two glycosyltransferases might be responsi-
ble for the transfer of l-2-deoxy-fucose (PM100117) 
or l-rhodinose (PM100118) to the second glycosyla-
tion position. Finally, the last glycosyltransferase would 
transfer l-rhodinose to the NQ moiety. Carbons 16 and 
17 of the aglycone contain a keto and a hydroxyl group, 
respectively. These oxygenations could be introduced at 
any step of PM100117/18 biosynthesis, after completion 
of the polyketide biosynthesis, as a tailoring modifica-
tion. We have shown that the putative cytochrome P450 
monooxygenase GonCP is responsible, at least, for C16 
oxygenation (Fig.  8). There is not a clear candidate for 
C17 oxygenation, being the closest orf9. Deletion of orf9, 
which codes for a putative dioxygenase and lies outside 
the PM100117/100118 cluster boundaries, does not show 
any effect on C17 hydroxylation (Fig.  6). However, the 
involvement of gonCP acting as a multifunctional oxyge-
nase in C17 modification cannot be excluded. The oxy-
genation of consecutive carbons at polyketide aglyca by 
multifunctional cytochrome P450 monooxygenases has 
been previously reported [48]. Taking this into consid-
eration we cannot discard the possibility of orf9 product, 
or any other oxygenase coding gene at S. caniferus GUA-
06-05-006A chromosome, complementing the putative 
GonCP C17 oxygenation in ΔgonCP mutant strain. Four 
genes code for putative transcriptional regulators belong-
ing to the MarR (GonMR) and LuxR (GonL1, GonL2 and 
GonL3) family, indicating that PM100117/18 biosynthesis 
might be subjected to a tight transcriptional regulation. 
Genetic engineering data suggest that proteins GonMR 
and GonL1 act as putative transcriptional activators. This 
is an interesting finding because MarR transcriptional 
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activators have been rarely described in the literature 
[49]. However, other mechanisms can also be considered 
regarding the mode of action of GonMR, such as a dual 
role as activator-repressor [50] or co-activator.
The noticeable structural similarity of the NQ unit to 
MK induced us to envisage a connection between the 
biosynthesis of both compounds (Fig.  5). This hypothe-
sis is further supported by the presence in the cluster of 
four genes (gonM1, gonM2, gonM3 and gonM4), coding 
for proteins highly identical to those involved in the early 
steps of MK biosynthesis via futalosine [33–35]. Based 
on their assigned putative functions, GonM1 (MqnA), 
GonM2 (MqnC) and GonM4 (MqnD) could catalyze 
three of the four reaction steps leading to the biosyn-
thesis of DH6N, which, according to our model, defines 
the branching point towards NQ and MK biosynthesis 
(Fig.  5). Even though C2-methylation of the NQ qui-
none ring could occurs at any step of its biosynthesis, it 
is very plausible that this reaction delivers DH6N to the 
NQ branch. Deletion of gonM4 diminishes PM100117/18 
production, and leads to the accumulation of biosyn-
thetic intermediates lacking the NQ unit (Fig.  7c). This 
result confirms the involvement of gonM4 in NQ bio-
synthesis. However, in contrast to gonP8−, ΔgonMT, 
ΔgonSL, ΔgonS1 and ΔgonS2 mutant strains, in which 
PM100117/18 biosynthesis is completely abolished, 
in ΔgonM4 a low PM100117/18 production level can 
be detected (Fig.  7a). This indicates that the additional 
mqnD homologue, present outside the PM100117/18 
gene cluster, is functional and able to partially comple-
ment the loss of gonM4. We do not fully understand the 
role of duplicated MqnA, MqnC and MqnD gene func-
tions in the genome. However, we can speculate that the 
presence in the cluster of dedicated mqnA, mqnC and 
mqnD genes leading to DH6N biosynthesis could offers 
two main advantages. One is to provide sufficient sup-
ply of DH6N, which is probably a limiting intermediate 
as it is common to MK and NQ biosynthesis. The second 
advantage could be to facilitate a coordinated regulation 
with other genes involved in PM100117/18 biosynthesis, 
thus ensuring an optimal PM100117/18 production when 
these are required. To date, this is the first time that MK 
biosynthesis is described as a nexus between second-
ary and primary metabolism. Nonetheless, the existence 
of duplicated gene homologues in a single genome, one 
being part of the primary metabolism and the other pre-
sent in a secondary metabolites gene cluster, has been 
frequently described for genes (ccr) coding for crotonyl-
coA carboxylase/reductase. Multiple ccr homologous 
have been identified in gene clusters for the biosynthe-
sis of various polyketide natural products [51–54]. As 
we have speculated for the presence of MK biosynthesis 
genes in the PM100117/18 gene cluster, the role of ccr 
duplications has also been postulated to be the supply of 
sufficient precursor building blocks for polyketide bio-
synthesis [51].
The generation of PM100117/18 structural analogues 
with improved antitumor activity relative to their natu-
ral products, represents a substantial achievement of this 
work. These derivatives were accomplished by a genetic 
manipulation, gonCP deletion, leading to a minor modi-
fication of PM100117/18 structure, the loss of a keto 
functional group. The twofold to fourfold improvement 
of antitumor activity showed by these derivatives is an 
interesting finding because the generation of truncated 
products, or even the removal of minor structural ele-
ments of a natural compound, often affects bioactivity 
negatively [55]. For instance, deletion of a gene coding 
for a cytochrome P450 monooxygenase of the pimaricin 
gene cluster in S. natalensis conduces to the produc-
tion of analogue 4,5-deepoxypimaricin, which differs 
from the natural compound in a single oxygenation and 
shows a diminished antibacterial activity relative to the 
parental product [56]. Similar results have been reported 
on the pikromycin analogues neopikromycin and nar-
bomycin produced by S. venezuelae, which lack a single 
hydroxyl group at different positions of the polyene ring 
and possess a noticeably reduced antibacterial activity 
[57]. Instead, most of the reported genetic engineering 
approaches, leading to the generation of improved bio-
active analogues, consist of the addition or replacement 
of structural components in the parental product [17, 
58]. In this regard, cytochrome P450 monooxygenases 
have been frequently contemplated as promising tar-
gets for engineering the biosynthesis of novel therapeu-
tic natural compounds. As an example, replacement of 
the C16 carboxyl on the nystatin analogue S44HP with 
a methyl group by mutation of a P450 monooxygenase 
gene, yielded a twofold more active antifungal analogue 
[59]. Herein, compounds 5 and 6 has been only assessed 
for in vitro cytotoxicity against different tumor cell lines. 
However, aside from an enhanced bioactivity, structural 
modifications frequently yield derivatives with other 
additional desirable pharmacological properties, such as 
lower toxicity or improved solubility [59–61]. In future 
works some of these properties of compounds 5 and 6 
might also be addressed.
On the other hand, the loss of the NQ unit caused 
in vitro cytotoxicity decay, indicating that this moiety is 
central to PM100117/18 antitumor activity. Curiously, 
two compounds structurally related to PM100117/18, 
langkolide [26] and GT35 [27], which harbor a similar 
napthtoquinone moiety, also possess cytotoxic activ-
ity. Furthermore, the anti-proliferative effect of MKs on 
tumor cells both in  vitro and in  vivo has been repeat-
edly reported [62, 63]. Conversely, other macrolides 
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structurally resembling PM100117/18 but lacking a 
napthtoquinone unit, such as liposidolide A [64] and 
polaramycin [65], exhibit antifungal and antibacterial but 
not antitumor activity. All together, these observations 
suggest the idea that PM100117/18 cytotoxic activity 
could, to large extent, stems from the NQ moiety.
The availability of the PM100117 and PM100118 gene 
cluster, and the genetic insights into their biosynthesis, 
will help to understand how similar natural compounds 
are produced. This information enables the engineer-
ing of more derivatives with improved pharmacological 
properties such as an enhanced biological activity.
Conclusions
PM100117 and PM100118 are members of a group of gly-
cosylated compounds hallmarked by the presence in their 
structures of a NQ chromophore structurally resem-
bling MK. Our results show that biosynthesis of the NQ 
chromophore is a complex process that involves diverse 
enzymes and which is connected to primary metabo-
lism. The presence in secondary metabolite gene clusters 
of certain primary metabolism genes may be explained 
in terms of a sufficient supply of limiting intermediates. 
This connection of secondary metabolism with MK bio-
synthesis has never been reported before. A similar situ-
ation might be encountered in the future when other 
gene clusters for natural products structurally related to 
PM100117/18 will be characterized. On the other hand, 
the analysis of PM100117/18 analogues has shown inter-
esting insights into the structure-bioactivity relation-
ship of these family of natural products. Removal of the 
C16 keto group leads to an increased antitumor activity 
of both the PM100117 and PM100118 derivative. How-
ever, the overall cytotoxicity level showed by compound 
5 is higher than the observed in compound 6. This sug-
gests that PM100117 could be a more promising target 
to undertake other structural modifications. In addition, 
based on the results presented in this work and previ-
ously described data on similar compounds, the presence 
of NQ moieties might be a predictive structural feature of 
cytotoxic activity. This issue could be taken into account 
at future screening for novel antitumor natural products.
Methods
Bacterial strains, tumor cell lines, media and cultivation 
conditions
Unless otherwise indicated, media used in this work have 
been described in Kieser et  al. [66]. The PM100117/18 
producer strain S. caniferus GUA-06-05-006A [25] 
was routinely grown in MA medium (2.1  % morpho-
linepropanesulfonic acid, 0.5  % glucose, 0.05  % yeast 
extract, 0.05 % meat extract, 0.1 % casaminoacids, pH 7.0 
adjusted with KOH). The Escherichia coli strains used as 
host for cloning (DH10B) [67] and for intergeneric con-
jugation (ET12567/pUB307) [66] were grown in 2× TY 
medium supplemented, when required, with the appro-
priate antibiotic for plasmid selection. For metabolite 
production, a seed culture was grown in 50-ml falcon 
tubes containing 5 ml TSB medium on a rotary shaker at 
250 rpm and 30 °C for 24 h. Then, 1.5 ml of the seed cul-
ture was used to inoculate 25 ml of SM medium (1 % glu-
cose, 0.4 % yeast extract, 0.4 % peptone, 0.4 % K2HPO4, 
0.2  % KH2PO4, 0.05  % MgSO4, pH 7.0 adjusted with 
KOH) supplemented with 10.3  % sucrose in a 250-ml 
shake flask. The culture was continued at 30 °C for 7 days 
with constant shaking at 200  rpm. Large-scale fermen-
tations for compound purification were carried out for 
9 days in a 2.5 L culture final volume inoculated (5 % v/v) 
with a seed culture grown for 72 h.
A-549 (ATCC CCL-185), lung carcinoma; HT-29 
(ATCC HTB-38), colorectal carcinoma and MDA-
MB-231 (ATCC HTB-26), breast adenocarcinoma cell 
lines were obtained from ATCC (http://www.lgcstand-
ards-atcc.org/). Cell lines were maintained in RPMI 
medium 1640 (Gibco-RBL) supplemented with 10 % fetal 
calf serum (FCS), 2 mM l-glutamine and 100 U/mL peni-
cillin and streptomycin, at 37  °C and 5 % CO2.
Analysis of metabolite production and compound 
purification
Samples (3  ml) from S. caniferus GUA-06-05-006A 
whole-cultures (see above) were mixed with an equal vol-
ume of ethyl acetate and incubated at room temperature 
for 2 h. The organic phase was then recovered by centrif-
ugation (3000×g, 10 min) and evaporated in vacuo. The 
residue was dissolved in methanol:DMSO (1:1) to per-
form UPLC and LC-MS analyses as described elsewhere 
[68].
For the purification of compounds 3, 4, 5 and 6, myce-
lia of the corresponding producing strains were separated 
from the culture by centrifugation and extracted twice 
with ethyl acetate. The supernatants were filtered and 
applied to a solid-phase extraction cartridge (Sep-Pak 
Vac C18, 10  g, Waters) that had been fitted with a per-
forated stopper pierced by a stainless steel HPLC tubing. 
The culture broth was applied by means of a peristaltic 
pump and subsequently the cartridge was connected to 
a HPLC quaternary pump (model 600E, Waters). The 
retained material was eluted with a mixture of methanol 
and 0.05  % trifluoroacetic acid (TFA) in water. A linear 
gradient from 0 to 100 % methanol in 60 min, at 10 ml/
min, was used. Fractions were taken every 5  min, col-
lected on 5 ml of 0.1 M phosphate buffer, pH 7.0 and ana-
lyzed by UPLC. Those fractions containing the desired 
compounds were evaporated in vacuo and subsequently 
re-dissolved in a small volume of a mixture of DMSO and 
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methanol (50:50). The organic extract of the culture pel-
lets was similarly evaporated and re-dissolved. The com-
pounds of interest were purified by preparative HPLC 
using a SunFire C18 column (10  µm, 10  ×  250  mm, 
Waters). Compounds were chromatographed with mix-
tures of acetonitrile or methanol and 0.05  % TFA in 
water in isocratic conditions optimized for each peak, 
at 7  ml/min, and were always collected on 0.1  M phos-
phate buffer, pH 7.0. Compound 5 was purified with 55 % 
acetonitrile in a first step and with 82  % methanol in a 
second step. Compound 6 was purified with 55  % ace-
tonitrile in a first step and with 85 % methanol in a sec-
ond step. Compounds 3 and 4 were purified with 32  % 
acetonitrile in a first step and with 37 % acetonitrile in a 
second step. After every purification step, the collected 
compounds were diluted fourfold with water and then 
applied to a solid-phase extraction cartridge (Sep-Pak 
C18, Waters). The cartridge was washed with water, the 
retained compound was eluted with methanol and dried 
in vacuo. Once the purification was finished, the com-
pounds were dissolved in a mixture of tert-butanol and 
water (1:1) and lyophilized.
In vitro cytotoxicity assay
Triplicate cultures were incubated for 72 h in the presence 
or absence of test compounds (at ten concentrations rang-
ing from 10 to 0.0026 mg/mL). For quantitative estimation 
of cytotoxicity, the colorimetric sulforhodamine B (SRB) 
method was used [69]. Briefly, cells were washed twice 
with PBS, fixed for 15 min in 1 % glutaraldehyde solution, 
rinsed twice in PBS, and stained in 0.4 % SRB solution for 
30 min at room temperature. Cells were then rinsed sev-
eral times with 1 % acetic acid solution and air-dried. Sul-
forhodamine B was then extracted in 10 mM trizma base 
solution and the absorbance measured at 490 nm. Using 
the mean  ±  SD of triplicate cultures, a dose-response 
curve was automatically generated using nonlinear regres-
sion analysis. Three reference parameters were calculated 
(NCI algorithm) by automatic interpolation: GI50 = com-
pound concentration that produces 50 % cell growth inhi-
bition, as compared to control cultures; TGI =  total cell 
growth inhibition (cytostatic effect), as compared to con-
trol cultures, and LC50  =  compound concentration that 
produces 50 % net cell killing (cytotoxic effect).
Mass spectra and structural elucidation
(+)-HRESIMS was performed on an Agilent 6230 time 
of flight LC/MS. NMR spectra were recorded on a Var-
ian “Unity 500” spectrometer at 500/125 MHz (1H/13C). 
Chemical shifts were reported in ppm using residual 
CD3OD (d 3.31 for 1H and 49.0 for 13C) as internal ref-
erence. HMBC experiments were optimized for a 3JCH of 
8 Hz. ROESY spectra were measured with a mixing time 
of 500  ms. The structures were established by 1H- and 
13C-NMR and two dimensional NMR experiments cor-
relation spectroscopy (COSY), heteronuclear multiple 
quantum coherence (HMQC), heteronuclear multiple-
bond correlation (HMBC).
DNA manipulation and plasmids construction
The isolation and manipulation of DNA were carried out 
following standard general methods previously described 
for E. coli [70] and Sreptomyces [66]. PCR amplifications 
were conducted by using Herculase II Fusion polymerase 
(Agilent Technologies) with a touchdown PCR proce-
dure. The termocycler (SureCycler 8800, Agilent Tech-
nologies) was programmed as follow: initial denaturation 
at 99.9 °C for 4 min; 20 cycles of 99.9 °C for 20 s, 65–45 °C 
touchdown for 20  s and 72  °C for tx (20  s/kb) min fol-
lowed by 10 cycles of 99.9 °C for 20 s, 60 °C for 20 s and 
72 °C for tx (20 s/kb) min. Final extension was performed 
at 72  °C for 3  min. PCR products of the expected size 
were gel-purified and sequenced.
A detailed description of the construction of plas-
mids used in this work can be found in Additional file 3: 
Methods S1. Plasmids for inactivation of genes gonP1 
and gonP8 were constructed in the conjugative plasmid 
pOJ260 [71], which lacks the capacity to replicate in 
Streptomyces and carries the aac(3)IV gene marker that 
confers resistance to apramycin (ApmR). To achieve the 
single deletion of genes gonM4, gonMT, gonSL, gonS1, 
gonS2, gonCP, gonMR, gonL1, orf9, orf10, orf11 and orf13, 
DNA sequences flanking the target genes were ampli-
fied with the primer pairs designated in Additional file 3: 
Table S1 and cloned at both sides of the aac(3)IV gene in 
plasmid pEFBA-oriT [72]. The hygromycin B resistance 
(HygR) gene marker, hyg, was then extracted from plas-
mid pLHyg [73] and introduced in the deletion plasmids 
(Additional file  3: Methods S1). Gene hyg allows recog-
nizing clones in which a complete gene replacement by 
a double cross-over has taken place (HygS ApmR) from 
those in which a single cross-over event has integrated 
the deletion plasmid into the chromosome (HygR ApmR). 
A suitable plasmid backbone to accomplish the comple-
mentation of ApmR mutants was constructed as follows. 
The integrative plasmid pSETec [68], which harbors the 
constitutive ermE*p promoter, was digested with NcoI. 
A 1.6  Kb fragment containing hyg was extracted from 
pLHyg by NheI/SpeI digestion. The linearized pSETec 
plasmid and the pLHyg NheI-SpeI fragment were then 
blunt-ended with the Klenow fragment of DNA polymer-
ase I and ligated to afford plasmid pSETHe. Complemen-
tation plasmids were generated by inserting the target 
genes into the XbaI/EcoRV sites of pSETHe, under the 
transcriptional control of the ermE*p promoter (Addi-
tional file 3: Methods S1).
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Gene mutation and complementation by intergeneric 
conjugation
Plasmids pOJ-gonP1 and pOJ-gonP8, pD-gonM4, pD-
gonMT, pD-gonSL, pD-gonS1, pD-gonS2, pD-gonCP, 
pD-gonMR, pD-gonL1, pD-orf9, pD-orf10, pD-orf11 and 
pD-orf13 (Additional file 3: Methods S1) were transferred 
into S. caniferus GUA-06-05-006A by intergeneric con-
jugation to generate the mutant strains gonP1−, gonP8−, 
ΔgonM4, ΔgonMT, ΔgonSL, ΔgonS1, ΔgonS2, ΔgonCP, 
ΔgonMR, ΔgonL1, Δ5201, Δ5257, Δ5259 and Δ5261, 
respectively. A standard conjugation procedure [66] with 
minor modifications was followed. Briefly, S. caniferus 
GUA-06-05-006A mycelia fragments stored at −20  °C 
from a SMS culture (5  ml) supplemented with 10  mM 
MgCl2 were used as plasmid recipient. E. coli donor cells 
were grown to an absorbance of 0.6 at 600 nm in 2× TY 
media containing the appropriate antibiotics for plas-
mid selection and 10 mM MgCl2. Donor cells (5 × 10−8) 
were washed twice with 2× TY and mixed with mycelia 
in 2× TY to a final volume of 1 ml. The mating mixture 
was spread on mannitol-soya (MS) plates supplemented 
with 25  mM MgCl2 and incubated for 20  h at 30  °C. 
Plates were then overlayed with 3  ml of SNA contain-
ing nalidixic acid (0.6 mg) and apramycin (1.2 mg), and 
further incubated for 7–10  days. Exconjugants poten-
tially harboring a gene deletion were transferred to MA 
plates with and without hygromycin B (100  µg/ml) and 
cultivated for 2 days. After several rounds of non-selec-
tive growth, Hygs recombinants were selected for gene 
replacement confirmation by PCR. Likewise, gonP1− and 
gonP8− exconjugants were refreshed in MA plates with 
nalidixic acid and apramycin and tested for correct gene 
inactivation by PCR (Additional file  3: Table S1). The 
resulting mutant strains were complemented with the 
conjugative plasmids pSETHe, pC-gonP8, pC-gonM4, 
pC-gonMT, pC-gonSL, pC-gonS1, pC-gonS2, pC-gonCP, 
pC-gonMR and pC-gonL1 (Additional file  3: Methods 
S1), generating the strains GUA-pS, CPgonP8, CPgonM4, 
CPgonMT, CPgonSL, CPgonS1, CPgonS2, CPgonCP, 
CPgonMR and CPgonL1, respectively. Selection of excon-
jugants carrying the corresponding complementation 
plasmid was performed by overlying conjugation plates 
with 3 ml of SNA containing nalidixic acid (0.6 mg) and 
hygromycin (2 mg).
Sequencing and bioinformatics analysis
The S. caniferus GUA-06-05-006A chromosome was 
sequenced at Lifesequencing Ltd., Valencia, Spain by 
Roche/454 pyrosequencing [74] on a Genome Sequenc-
ing FLX platform. The genome was assembled in the 
Newbler assembler package [75] version 2.8 by using 
default parameters. Identification of gene clusters for 
biosynthesis of secondary metabolites was performed by 
the antibiotics and secondary metabolite analysis shell: 
antiSMASH 3.0.4 [22]. Annotation of ORFs within the 
PM100117/18 biosynthesis gene cluster was based on 
database searching of the corresponding proteins car-
ried out by BLAST algorithm [76] at the National Center 
for Biotechnology Information (NCBI). Additional 
sequence alignments were conducted by ClustalW2 [77] 
and EMBOSS needle [78] from the European Molecular 
Biology Laboratory (EMBL). Prediction of transmem-
brane domains was performed by TMHMM Server v. 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/).
The nucleotide sequence of the PM100117/18 gene 
cluster was deposited in GeneBank (accession numbers: 
LN997801 and LN997802).
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